Network origin in David Horn first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
Mid-Atlantic BioTherapeutics, Inc.
 Mid-Atlantic BioTherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Mid-Atlantic BioTherapeutics, Inc. is a clinical-stage pharmaceutical company focused on the clinical development and commercialization of a novel anti-infective therapeutic approach, which is immunotherapy for infectious diseases. The company was founded by David Horn, David Jobes, and Jean-Pierre Gagnon in 2011 and is headquartered in Doylestown, PA.
4
| Private Company | Miscellaneous Commercial Services | 4 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to David Horn via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| MCDONALD'S CORPORATION | Restaurants | Corporate Officer/Principal | |
| University of Oxford | College/University | Doctorate Degree | |
| The Reed Institute | College/University | Undergraduate Degree | |
| TALI DIGITAL LIMITED | Packaged Software | Chief Executive Officer | |
| Tulane University (Louisiana) | College/University | Doctorate Degree | |
| University of California, Davis | College/University | Doctorate Degree | |
National Institutes of Health
 National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | General Government | Corporate Officer/Principal | |
| US Defense Advanced Research Projects Agency | Sovereign | Corporate Officer/Principal | |
| LaTrobe University | College/University | Undergraduate Degree | |
Presidio Pharmaceuticals, Inc.
 Presidio Pharmaceuticals, Inc. BiotechnologyHealth Technology Presidio Pharmaceuticals, Inc. discovers and develops small-molecule antiviral therapeutics. Its products in pipeline include NS5A, PPI-668 and PPI-383 for treating hepatitis C virus infections. The company was founded by Omar K. Haffar, Antoun Nabhan and David V. Jobes in March 2006 and is headquartered in San Francisco, CA. | Biotechnology | Founder | |
Numerate, Inc.
 Numerate, Inc. Information Technology ServicesTechnology Services Numerate, Inc. operates as a technology platform company that leverages proprietary algorithms and cloud computing to transform the drug design process. The company was founded by Guido Lanza, Nigel P. Duffy, John Hampton Griffin and Brandon Allgood in 2007 and is headquartered in San Francisco, CA. | Information Technology Services | President | |
Four Seasons Ventures LLC
 Four Seasons Ventures LLC Investment ManagersFinance Four Seasons Ventures LLC (Four Seasons Ventures) is a venture capital firm founded in 2000 by Joel McCleary and Véronique Bardach. The firm is headquartered in Washington, District of Columbia. | Investment Managers | Private Equity Investor | |
Sanofi Pasteur VaxDesign Corp.
 Sanofi Pasteur VaxDesign Corp. Miscellaneous Commercial ServicesCommercial Services Sanofi Pasteur VaxDesign Corp. designs, develops, and manufactures in vitro models of the human immune system. The firm engages in preventing infectious disease by forecasting vaccine responses before clinical trials by providing predictive in vitro immunological models and assays. The company was founded by William Warren in 2004 and is headquartered in Orlando, FL. | Miscellaneous Commercial Services | Chairman | |
Carmot Therapeutics, Inc.
 Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Biotechnology | Corporate Officer/Principal | |
| ANTERIS TECHNOLOGIES LTD | Medical Specialties | Chief Operating Officer | |
| OPYL LIMITED | Internet Software/Services | Chairman | |
| CANN GROUP LIMITED | Agricultural Commodities/Milling | Chairman | |
| LTR PHARMA LIMITED | Biotechnology | Director/Board Member |
Statistics
International
| United States | 19 |
| Australia | 7 |
| United Kingdom | 2 |
Sectoral
| Health Technology | 8 |
| Consumer Services | 7 |
| Technology Services | 4 |
| Government | 3 |
| Commercial Services | 3 |
Operational
| Director/Board Member | 13 |
| Corporate Officer/Principal | 8 |
| Chairman | 4 |
| Doctorate Degree | 3 |
| President | 3 |
Most connected contacts
| Insiders | |
|---|---|
| Michael J. Goldblatt | 12 |
| Julian Chick | 8 |
| David V. Jobes | 8 |
| Jean-Pierre Gagnon | 1 |
- Stock Market
- Insiders
- David Horn
- Company connections
